



The **FOURIER** Trial

Sabina A. Murphy, Terje R. Pedersen, Zbigniew A. Gaciong,
Richard Ceska, Marat V. Ezhov, Derek Connolly, Oleg Kraydashenko,
J. Wouter Jukema, Kalman Toth, Matti J. Tikkanen, Kyungah Im,
Stephen D. Wiviott, Christopher Kurtz, Narimon Honarpour,
Robert P. Giugliano, Anthony C. Keech, Peter S. Sever,
Marc S. Sabatine


On behalf of the FOURIER Investigators

*American Heart Association Scientific Sessions
November 13, 2017*



PCSK9 blocks LDLR-Recycling

More LDL-Receptor
Less LDL-C



More LDL-Receptor
Less LDL-C

Statin vs. Statin + PCSK9 antibody

27,564 high-risk, stable patients with established CV disease
(prior MI, prior stroke, or symptomatic PAD)


Screening, Lipid Stabilization, and Placebo Run-in
High or moderate intensity statin therapy (\pm ezetimibe)

LDL-C ≥ 70
non-HDL-C ≥ 55


RANDOMIZED
DOUBLE

Evolocumab SC
140 mg Q2W or 420 mg QM

Follow-up Q



Statin vs. Statin + PCSK9 antibody





Hypothesis




PCSK9 inhibition with evolocumab reduces
total vascular events,
both *first* and *recurrent!*






Type of Primary Endpoint Events




Total PEP = 4906






Total Primary Endpoint Events






Total Primary Endpoint Events





Total Primary Endpoint Events






Total Primary Endpoint Events



Number of Events Prevented for 1,000 Patients Treated with Evolocumab for 3 Years






Total Primary Endpoint Events




Number of Events Prevented for 1,000 Patients Treated with Evolocumab for 3 Years





FOURIER subanalysis PAD

CV Death, MI or stroke in patients with and without PAD



Bonaca M | LBS-02
Bonaca M et al, Circulation 2017;137. DOI: 10.1161/CIRCULATIONAHA.117.032235




An Academic Research Organization of
Brigham and Women's Hospital and Harvard Medical School



FOURIER subanalysis PAD

Major adverse limb events






FOURIER subanalysis history of MI – results

Benefit of EvoMab based on time from qualifying MI

Benefit of EvoMab based on multivessel disease





Summary



- **Addition of the PCSK9 inhibitor evolocumab to statin therapy improved clinical outcomes with reductions in total primary endpoint events**
 - Driven by reductions in MI, stroke, and coronary revascularization
- **Taking into account total events more than doubled the number of events prevented with evolocumab compared with first events only**
- **Patients with PAD experienced the greatest benefit from evolocumab treatment**

